Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mus musculus

ABSTRACT: Dietary Lactobacillus-derived exopolysaccharide enhances immune checkpoint blockade therapy

PROVIDER: PRJDB12989 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	DRR346065_1.fastq.gz	Fastqsanger.gz
	DRR346065_2.fastq.gz	Fastqsanger.gz
	DRR346066_1.fastq.gz	Fastqsanger.gz
	DRR346066_2.fastq.gz	Fastqsanger.gz
	DRR346067_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 156

Similar Datasets

IL-17A Neutralization Prevents Immune Checkpoint Inhibitor-Associated Myocarditis and Synergistically Enhances Immune Checkpoint Blockade Therapy

Project description:IL-17A Neutralization Prevents Immune Checkpoint Inhibitor-Associated Myocarditis and Synergistically Enhances Immune Checkpoint Blockade Therapy

| PRJNA1266108 | ENA

Comparative proteome of membrane proteome from Lactobacillus fermentum MI37

Project description:Recent findings have positioned the gut microbiota as a promising target to enhance cancer immunotherapy. However, the specific microbial molecules that drive anti-tumor immunity remain unclear. Here, we identify a human-derived strain, Lactobacillus fermentum MI37, that potentiates anti-cancer immune responses and synergizes with anti-PD-1 immune checkpoint blockade. MI37 robustly induces IFN-γ production by splenocytes, with minimal IL-10 induction, and enhances cytotoxic T lymphocyte infiltration and inflammatory gene expression within tumors in a syngeneic mouse model. Remarkably, heat-killed MI37 retains its immunostimulatory effects and anti-tumor efficacy. Fractionation experiments implicate lipoteichoic acid (LTA) as the active component, and LTA mimics the effects of MI37 on IFN-γ production and CD8⁺ T cell activation. Genomic and proteomic profiling reveals MI37-specific pathways involved in teichoic acid biosynthesis, including a unique sulfatase N-terminal domain-containing protein with an LTA synthase domain. These findings highlight the potential of LTA-producing probiotics as microbial adjuvants to improve the efficacy of cancer immunotherapy.

2026-05-25 | PXD071250 | Pride

MHC II immunogenicity shapes the neoepitope landscape in human tumors

Project description:DeepNeo predicts immunogenic neoantigens for both MHC I and II responsive to immune checkpoint blockade therapy. Furthermore, spontaneous immunity was observed in pancancer manner for MHC II.

2022-11-14 | PRJEB57400 | EVA

Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation

Project description:Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation

| PRJNA718568 | ENA

scRNA-seq analysis demonstrate alterations in TICs of the TME during TREM1 inhibition and anti-PD-1 treatment in B16F10 melanoma

Project description:To comprehensively characterize the changes within the TME during TREM1 deficiency and anti-PD-1 immune checkpoint blockade therapy, we performed scRNA-seq analysis of the CD45+ TICs in melanoma-bearing C57BL/6 mice receiving the various treatments. We analyzed approximately 8,249 CD45+ cells from the treatment groups with t-SNE analysis, identifying 10 distinct clusters of tumor-infiltrating immune cells

2023-09-27 | E-MTAB-13300 | biostudies-arrayexpress

Therapeutic Targeting of the p300/CBP Bromodomain Enhances the Efficacy of Immune Checkpoint Blockade Therapy

Project description:Therapeutic Targeting of the p300/CBP Bromodomain Enhances the Efficacy of Immune Checkpoint Blockade Therapy

| PRJNA1232709 | ENA

USP5 stabilizes YTHDF1 to control cancer immune surveillance through mTORC1-mediated phosphorylation

Project description:N6-methyladenosine (m6A) binding protein YTHDF1 is frequently upregulated in various cancers and its depletion enhances the efficacy of immune checkpoint blockade (ICB) therapy. This study reveals that USP5 interacts with YTHDF1, preventing its K11-linked polyubiquitination, thereby stabilizing YTHDF1 and promoting its oncogenic properties. In response to insulin, mTORC1 phosphorylates USP5, facilitating its dimerization and subsequent binding to YTHDF1, while the CUL7-FBXW8 complex promotes its degradation. Notably, YTHDF1 or USP5 deficiency increases PD-L1 expression and impairs immune response gene expression, contributing to immune evasion. Combining USP5 inhibitors with anti-PD-1 therapy enhances antitumor T-cell immunity and improves tumor regression in mouse models. Thus, USP5 may serve as a biomarker for stratifying patients for anti-PD-1 therapy, suggesting a novel strategy of combining USP5 inhibition with PD-(L)1 blockade to enhance cancer treatment efficacy.

2024-12-05 | GSE278264 | GEO

Mus musculus

Project description:Inhibition of integrin alpha-V/beta-6 sparks T-cell anti-tumor response and enhances immune checkpoint blockade therapy in colorectal cancer

| PRJNA798222 | ENA

BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy.

Project description:BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy.

| PRJNA1292467 | ENA

MDM2 inhibition enhances immune checkpoint inhibitor therapy in melanoma

Project description:MDM2 inhibition enhances immune checkpoint inhibitor therapy in melanoma

| PRJNA764915 | ENA